Cytovene (ganciclovir) / Roche - LARVOL DELTA

Bilateral cytomegalovirus retinitis in the setting of acquired lymphopenia following administration of bendamustine. (PubMed, Retin Cases Brief Rep) - "Bendamustine can cause profound lymphopenia with reduced CD4 T-cell levels; risk of herpes virus retinitis is elevated in the setting of such immunosuppression. In HIV-negative patients, there is no specific treatment to raise the CD4 count. Prompt initiation and continued administration of systemic and local antiviral treatment can lead to disease control and preservation of vision while awaiting immune reconstitution."

Journal • Cytomegalovirus Infection • Follicular Lymphoma • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Ocular Inflammation • Oncology • Ophthalmology • Retinal Disorders • CD4

Medically Refractory Acute Severe Ulcerative Colitis Complicated by Cytomegalovirus Managed With Diverting Loop Ileostomy During Pregnancy: A Case Report (ACG 2026) - "Case Description/ A 23-year-old woman with a 10-year history of ulcerative pancolitis being treated with upadacitinib 45mg and prednisone 40mg was transferred from another hospital at 25 weeks gestation with 2 weeks of bloody diarrhea. She had loss of response or non-response to adalimumab, vedolizumab, ustekinumab, and prior response to infliximab induction but lost response after switching to subcutaneous maintenance...Intravenous solumedrol was started on day 1 and upadacitinib was continued...She continued infliximab and valganciclovir and tapered off prednisone outpatient...Secondly, the management of CMV colitis during pregnancy may differ from non-pregnant individuals, as ganciclovir is typically avoided due to potential risks to the fetus...Figure: Figure 1: Representative image from flexible sigmoidoscopy showing severe colitis with erythema and ulcerations. Figure: Figure 2: Picture of the patientâs ostomy wound two weeks post-op."

Case report • Clinical • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • CRP

From Epiglottis to Colon: Aerodigestive Ulceration in Crohnâs Disease, Not Opportunistic Infection (ACG 2026) - "History included small-bowel resection, right hemicolectomy for stricturing disease, and ganciclovir-treated CMV colitis. The patient received infliximab followed by vedolizumab, with an epiglottic ulcer developing in the interval between these agents. Persistent disease prompted escalation to ustekinumab, addition of short-term exclusive enteral nutrition for induction, and current combined ustekinumab and upadacitinib, without sustained remission."

Anorexia • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Respiratory Diseases • Sarcoidosis • Tuberculosis

Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial. (ASCO 2025) - P1 | "Dexamethasone premedication was limited to C0–1...One DLT occurred at DL2 (Gr 3 CMV colitis on day 48; resolved with tx delay and ganciclovir)... LINVO + BTZ induced high response rates, with encouraging early DOR and PFS, in a population that was mostly PI-refractory. Safety was consistent with the known profile of each drug, and risk of Gr 3–5 infection was similar to LINVO monotherapy. These data will inform LINVO combination strategies for earlier LoT."

Clinical • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • Thrombocytopenia

Syphilitic Neuroretinitis with Positive Cytomegalovirus Serology in an Immunocompetent Adolescent: A Case Report. (PubMed, Case Rep Ophthalmol) - "The patient was treated with intravenous ceftriaxone and ganciclovir followed by oral valganciclovir. This case highlights the importance of comprehensive infectious evaluation in neuroretinitis, even in immunocompetent individuals. Early diagnosis and appropriate targeted antimicrobial therapy are essential to prevent permanent visual loss."

Journal • Cytomegalovirus Infection • Genetic Disorders • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Macular Edema • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Retinal Disorders

Differentiating poor prognosis from treatment-related fluctuations in Guillain-Barré syndrome for repeating immunoglobulin treatment: an illustrative case report. (PubMed, Front Immunol) - "The patient received IVIG and ganciclovir...Careful distinction between poor prognosis, nonresponse, and treatment-related fluctuation is essential because it directly influences therapeutic decision-making. Close monitoring, individualized immunotherapy, intensive supportive care, and early rehabilitation remain central to optimizing outcomes in severe GBS."

IO biomarker • Journal • Cytomegalovirus Infection • Gastrointestinal Disorder • Pain • Respiratory Diseases

Maribavir efficacy and safety by baseline neutropenia status in solid organ transplant recipients with refractory cytomegalovirus: post hoc analysis of phase 2 and 3 trials (TTS 2026) - P2, P3 | "Maribavir is an anti-CMV agent with lower incidence of myelosuppression than valganciclovir/ganciclovir in solid organ transplant (SOT) recipients treated for refractory CMV infection. This post hoc analysis of maribavir-treated SOT recipients with refractory CMV infection found comparable response rates and time to CMV clearance between patients with and without baseline neutropenia. Similar AE profiles were observed between groups. Although these findings are based on small sample sizes, particularly for moderate-to-severe neutropenia (Study 202 only), they support use of maribavir as a therapeutic option for SOT recipients with CMV infection with and without neutropenia."

Clinical • P2 data • Retrospective data • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Neutropenia • Solid Organ Transplantation • Transplantation

Real-world CMV hyperimmunoglobulin prophylaxis in heart and lung transplantation: one-year interim results from a prospective multicenter study (TTS 2026) - "Antiviral exposure during follow-up included valganciclovir (79%), ganciclovir (30%), letermovir (6%), and maribavir (5%). In this prospective real-world HTx and LuTx cohort, adjunctive CMVIG prophylaxis was associated with low rates of treatment-requiring CMV, CMV syndrome, and tissue-invasive disease at one year, with low rates of CMVIG-related adverse events. Final results from the complete 553-patient cohort will further clarify the role of CMVIG across CMV management settings in HTx and LuTx."

Clinical • Real-world • Real-world evidence • Cytomegalovirus Infection • Infectious Disease • Transplantation

Area under the curve-guided mycophenolate mofetil dose optimization in an ABO-incompatible Thai kidney transplant recipient with rare thrombocytopenia: A case report (TTS 2026) - "Her regimen included a single dose of rituximab, followed by tacrolimus, MMF (1.5 g/day), and prednisolone; cytomegalovirus prophylaxis with valganciclovir was also initiated 28 days prior to surgery due to the high risk of rejection...It was only after a further reduction to 750 mg/day that the AUC decreased into the therapeutic range (33 mg·h/L), allowing for the resumption of ganciclovir... Although routine TDM for MMF is not universally recommended, this case underscores its clinical benefit when managing thrombocytopenia through MMF AUC-guided dose adjustment in high-immunological-risk cases, such as ABO-incompatible transplants. This study indicates that MMF AUC-guided TDM is an essential tool for precise dose optimization, balancing the prevention of rejection with the mitigation of adverse drug events."

Case report • Clinical • Cytomegalovirus Infection • Hematological Disorders • Thrombocytopenia • Transplantation

Clinical outcome with low dose CMV prophylaxis in Indian kidney transplant recipients (TTS 2026) - "24 patients received Basiliximab induction, 25 rabbit-anti-thymocyte globulin (r-ATG) and 26 did not receive any induction agent besides steroids...One out of 75 patients developed CMV disease during follow up, and received IV ganciclovir therapy... Low dose valganciclovir seems to be effective in preventing CMV in low risk(R+) transplants but continues to be poorly tolerated with high incidence of leucopenia. Long term follow-up will assess the impact on burden of CMV disease and graft and patient survival."

Clinical • Clinical data • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Leukopenia • Nephrology • Transplantation

Topical versus oral antiviral therapy for cytomegalovirus anterior uveitis: a multicenter study in Taiwan. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "Compared with topical ganciclovir, oral valganciclovir is associated with a lower risk of recurrent and chronic CMV AU. Chronic and recurrent disease are associated with increased risk of glaucoma requiring intervention, and recurrent disease carries an additional risk of corneal decompensation."

Clinical • Journal • Cytomegalovirus Infection • Glaucoma • Ocular Inflammation • Ophthalmology • Transplantation • Uveitis

Early Initiation of Letermovir Prophylaxis Prevents Cytomegalovirus Infection After Liver Transplantation: A Prospective Single-Center Study (TTS 2026) - "Treatment was discontinued in cases of adverse events, CMV antigenemia, or CMV disease, with conversion to ganciclovir or valganciclovir as appropriate. Early initiation of letermovir prophylaxis within 2 weeks after liver transplantation effectively prevents CMV infection and is a safe strategy. These findings highlight the critical importance of early prophylactic intervention in optimizing CMV prevention."

Clinical • Cytomegalovirus Infection • Hepatology • Infectious Disease • Transplantation

CMV transplant nephritis and graft failure: A cautionary tale (TTS 2026) - "The patient received induction immunosuppression with alemtuzumab...The patient was treated initially with intravenous ganciclovir, briefly switched to foscarnet, and ultimately discharged on oral valganciclovir... CMV nephritis is a rare but serious complication of kidney transplantation associated with high rates of graft failure. This case highlights the importance of maintaining high clinical suspicion for CMV end-organ disease in patients with risk factors such as lymphocyte-depleting induction therapy, even in CMV-seropositive recipients. Early recognition through kidney biopsy and aggressive antiviral treatment are essential, though outcomes remain poor."

Chronic Kidney Disease • Cytomegalovirus Infection • Fibrosis • Focal Segmental Glomerulosclerosis • Gastrointestinal Disorder • Glomerulonephritis • Immunology • Infectious Disease • Nephrology • Transplantation • Vasculitis

New Strategies for the Management of Hospitalized AIDS Patients with Concurrent High CMV Viremia (ChiCTR) - P=N/A | N=440 | Not yet recruiting | Sponsor: The Second Hospital of Nanjing; The Second Hospital of Nanjing

New trial • Human Immunodeficiency Virus • Infectious Disease • CD4

A case report: Adenovirus nephritis with BK nephropathy after deceased donor kidney transplantation (TTS 2026) - "The patient was treated with reduced immunosuppression and ganciclovir...Treatment strategies include reduction of immunosuppression, antiviral therapy, and, in some cases, intravenous immunoglobulin. The clinical course was relatively favorable with appropriate intervention."

Case report • Clinical • Glomerulonephritis • IgA Nephropathy • Infectious Disease • Nephrology • Renal Disease • Transplantation

Real world efficacy of maribavir when used as pre-emptive therapy for cytomegalovirus reactivation in alloHCT patients who are intolerant, refractory or resistant (TTS 2026) - "Existing antivirals (val)ganciclovir and foscarnet have significant toxicities (myelosuppression and renal dysfunction) and often necessitate inpatient admissions. This real-world study demonstrates that MBV is an effective, well-tolerated antiviral when used as PET. It is beneficial in cases of bone marrow dysfunction and reduces inpatient hospitalisation days in patients who require foscarnet."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Cytomegalovirus Infection • Infectious Disease • Nephrology • Renal Disease

The rare entity of cytomegalovirus cholecystitis: A case report (TTS 2026) - "Despite absence of typical CMV associated symptomatology, ganciclovir was commenced due to the high viral load... CMV disease typically occurs within the first year following kidney transplantation, making late presentations diagnostically challenging. CMV cholecystitis is a rare manifestation of tissue-invasive disease in solid organ transplant recipients. This case highlights the diagnostic challenge posed by atypical CMV presentations and illustrates the importance of maintaining suspicion for atypical opportunistic infections in long-term transplant recipients who present with unexplained systemic inflammation and sepsis."

Case report • Clinical • CNS Disorders • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Infectious Disease • Inflammation • Septic Shock • Solid Organ Transplantation • Systemic Inflammatory Response Syndrome

Low level drug resistance linked to cytomegalovirus UL97 and UL27 mutations detected in maribavir clinical trials. (PubMed, Antiviral Res) - "Among 8 UL97 kinase variants tested, none were found to confer maribavir resistance, while amino acid substitution G598A conferred borderline ganciclovir resistance (1.9-fold increased 50% effective concentration [EC50]) and K599N did not (1.1-fold). Both resistant UL27 mutants were observed in connection with maribavir treatment failure, but L317V differs in being detected as an emergent mutation after 29 days of therapy rather than at baseline. The clinical significance of baseline and emergent UL27 mutations for maribavir therapy requires further surveillance."

Journal • Cytomegalovirus Infection

New 1,3-Oxazole and 1,2,4-Oxadiazole Derivatives as Novel Agents Against Human Rhinovirus and Cytomegalovirus. (PubMed, ChemMedChem) - "Compound 7 showed remarkable selectivity (SI = 465), outperforming ganciclovir (GCV, SI = 326)...Molecular docking suggested that derivatives 7, 10, 13, and 14 may target viral DNA polymerase, with binding energies from -8.8 to -9.7 kcal mol-1. These findings demonstrate that 1,3-oxazoles represent a promising chemotype for new antiviral candidates active against HCMV and HRV8."

Journal • Cardiovascular • CNS Disorders • Cytomegalovirus Infection • Infectious Disease • Respiratory Diseases

Reassessing Ganciclovir Renal Dose Adjustment Using CKD-EPI:A Population Pharmacokinetic Simulation Study (IDWeek 2026) - No abstract available

Clinical • PK/PD data • Infectious Disease

When Immune System and Herpes Virus Infection Collide: A Case of Severe Stromal Herpetic Keratitis in a Patient with Rheumatoid Arthritis Under Methotrexate. (PubMed, Int Med Case Rep J) - "A recurrent episode of HSVK was diagnosed, and treatment with 3 times daily oral acyclovir, 4 times daily 0.15% ganciclovir ophthalmic gel, and 3 times daily 0.15% topical dexamethasone was started. This case underscores how systemic immunomodulatory treatment may play a clinically relevant role in patients with recurrent HSVK. In selected cases, a conservative, surgery‑sparing approach through the optimization of systemic therapy can help promoting viral load control and corneal healing."

Journal • Herpes Simplex • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Keratitis • Ocular Inflammation • Ophthalmology • Pain • Rheumatoid Arthritis • Rheumatology

ANZTCT cytomegalovirus practice survey for allogeneic haemopoietic stem cell transplant and cellular therapy recipients in Australia and New Zealand. (PubMed, Intern Med J) - "Institutional preferences and medicine funding drives variability in ANZ practice. This leaves potential for healthcare inequity since newer antiviral agents are inconsistently used, contrasting with international guidelines."

Journal • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease • Pediatrics • Transplantation

Fracture healing requires proliferation of callus cells at early and mature stages of osteoblast differentiation. (PubMed, JCI Insight) - "First, mice expressing thymidine kinase (TK) in 3.6Col1a1-lineage cells were treated with ganciclovir (GCV) to ablate proliferating osteolineage cells for 5 or 10 days...Following fracture, each Cre;ROSA-TK mouse line exhibited decreased callus bone volume and a shift from callus bone to fibrous tissue. Therefore, during fracture repair, proliferation of callus cells at early and mature stages of osteoblast differentiation is critical to the formation of a mineralized callus that is essential for healing."

Journal • Musculoskeletal Diseases • Orthopedics • BGLAP

Multi-Criteria Decision Analysis using Physician Preferences from a Global Discrete Choice Experiment to Investigate the Selection of Preemptive Antiviral Treatments for Post-Hematopoietic Cell Transplant Cytomegalovirus Infection. (PubMed, Open Forum Infect Dis) - "Maribavir had a higher overall benefit-risk score than ganciclovir and foscarnet in both ANC cohorts. Within this MCDA framework, maribavir was preferred over valganciclovir, ganciclovir, and foscarnet for preemptive treatment of CMV after HCT."

Journal • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Neutropenia • Transplantation

Catastrophic Complications in Severe Crohn's Disease: A Case Highlighting the Consequences of Delayed Biologic Therapy, Undiagnosed CMV Colitis, and Substance Use Disorder (ACG 2026) - "Case Description/ A 63-year-old male with a history of ileocolonic Crohn's disease, tobacco use, and methamphetamine use presented with worsening abdominal pain, diarrhea, and anorexia. Maintenance therapy had been discontinued due to financial constraints, leading to cessation of infliximab and adalimumab...Histopathologic confirmation of CMV colitis was not available until eight days after the second surgery, and IV ganciclovir was initiated...Key lessons include:(1) steroid-refractory disease should be identified within 7 to 14 days, with prompt escalation to biologic therapy(2) detection of a positive blood CMV PCR in steroid-refractory IBD should prompt urgent tissue confirmation before surgical intervention(3) Nutritional status, smoking, and substance use, should be optimized prior to surgery and(4) early referral to tertiary IBD centers may improve outcomes. Figure: Timeline and root-cause analysis of factors contributing to catastrophic postoperative..."

Clinical • Anorexia • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Nicotine Addiction